Leucovorin (Folinic acid)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-LEUCOVORIN |
|---|---|
| Type | Médicament |
| Alias | Acide foliniqueLeucovorineЛейковорин (Фолінова кислота) |
| État | reviewed 2026-04-26 | pending_clinical_signoff |
| Maladies | DIS-BURKITT DIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-PDAC DIS-PTCL-NOS |
| Sources | SRC-NCCN-COLON-2025 |
Faits sur les drogues
| Catégorie | Folate réduit (5-formyltétrahydrofolate) — biomodulateur |
|---|---|
| Mécanisme | Tetrahydrofolate donor that stabilizes the 5-FU/thymidylate-synthase ternary complex, potentiating 5-FU cytotoxicity. NOT a chemotherapy agent itself in this role — it is given alongside 5-FU. Separately, high-dose leucovorin is used as MTX rescue. |
| Ukraine enregistrée | Vrai |
| NSZU remboursé | Vrai |
| Ukraine vérifiée pour la dernière fois | 2026-04-27 |
Notes
Most 5-FU regimens require leucovorin for activity modulation; doses are protocol-specific: Mayo Clinic (20 mg/m² IV bolus pre-5FU), Roswell Park (500 mg/m² IV 2-h infusion), de Gramont / FOLFOX / FOLFIRI (200-400 mg/m² IV 2-h infusion Day 1 ± Day 2). Levoleucovorin (l-isomer) is the active enantiomer; half the dose of racemic leucovorin (10 mg/m² Mayo equivalent). In high-dose methotrexate rescue: 15 mg PO/IV q6h starting 24 h post-MTX, continued until MTX level <0.05-0.1 µM (escalate dose if MTX clearance delayed). Critical safety point: leucovorin rescue dose must be matched to MTX level — under-rescue causes fatal MTX toxicity. UA: зареєстрований; НСЗУ-reimbursed for 5-FU modulation in CRC and as MTX rescue. Generic widely available.
Utilisé par
Protocole thérapeutique
REG-5FU-LV-BEV-CKD-MODIFIED- 5-FU + Leucovorine + Bevacizumab (sLV5FU2-Bev, CCR CrCl CKD sévère <30 — oxali/cabine dangereux)REG-BEMARITUZUMAB-MFOLFOX6- Bemarituzumab + mFOLFOX6 (FORTITUDE-101) — 1L FGFR2b-expression HER2- gaz non positif...REG-CODOX-IVAC-PROVEN-CNS- eviQ proven-CNS R-CODOX-M / R-IVAC reference for specialist reviewREG-CODOX-M-IVAC- Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 44...REG-FLOT- FLOTREG-FOLFIRI-BEV- FOLFIRI + Bevacizumab (ou ± cetuximab si le RAS-WT est à gauche)REG-FOLFIRINOX- FOLFIRINOXREG-FOLFOX- FOLFOX (mFOLFOX6)REG-FOLFOX-BEV- FOLFOX + BevacizumabREG-FOLFOX-CETUX- FOLFOX + CetuximabREG-FOLFOX-NIVO- FOLFOX + NivolumabREG-FOLFOXIRI-BEV- FOLFOXIRI + BevacizumabREG-MFOLFIRINOX- mFOLFIRINOX (FOLFIRINOX modifié, protocole PRODIGE-24)REG-NAL-IRI-5FU-LV-PDAC- Non...IRI + 5-FU/LV (PDAC, 2L nanoliposomal irinotecan)REG-NALIRIFOX- NALIRIFOXREG-PRALATREXATE-PTCL- Pralatrexate 30 mg/m2 IV hebdomadaire × 6 du cycle de 7 semaines (horaire PROPEL)REG-ZOLBETUXIMAB-CHEMO- Zolbetuximab + mFOLFOX6 (SPOTLIGHT) - 1L CLDN18,2-positif HER2-négatif gastrique/GEJ